Pay in 4 interest-free payments of $5.75 Learn more
Ships within 48 hours · Estimated delivery Oct 26 - Oct 31
glp-1 gip medication long term effects GLP-1R Agonists for Weight Loss supplements Flavor:Blood Orange MyGLP Challenge
MyGLP Challenge
The fix is straightforward
supplements
Flavor:Blood Orange
About the Company: • Daiichi Sankyo US is a global #biopharma leader focused on innovative oncology therapies • Merck Group (MSD) is a leading global pharmaceutical company specializing in breakthrough medicines • Both companies are pioneers in antibody-drug conjugate development About the Product: • #Ifinatamab deruxtecan (I-DXd) is a B7-H3–directed #ADC therapy • Designed to deliver #cytotoxic agents directly to cancer cells • Targets extensive-stage small cell lung cancer (#ES-SCLC) Key Highlights: • FDA Priority Review granted for #BiologicsLicense Application • Based on Phase 2 #IDEATE-Lung01 clinical data • Potential first-in-class #B7-H3 targeted therapy • Addresses patients progressing after platinum-based chemotherapy • #PDUFA decision expected in October 2026 Small cell #lungcancer remains one of the most aggressive cancers with limited treatment options after relapse, making targeted therapies like #ADCs highly promising
US$ 20.37
US$ 26.17
US$ 23.58
US$ 26.98
US$ 28.81
US$ 22.22
US$ 23.41
